Markets Are Already Pricing Successful Moderna Vaccine Shot
- Investors say bar was raised for next results to upend stocks
- Pfizer success had ‘spillover’ effect: Research Affiliates
Samples are removed from a freezer at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S.
Photographer: Adam Glanzman/BloombergThis article is for subscribers only.
The stakes are high for the results of Moderna Inc.’s coming Covid-19 vaccine trial. But as far as investors are concerned, the impact may already be in the price of financial assets.
The bar was raised for markets to rally following an announcement by Pfizer Inc. that its vaccine protected 90% of Covid-19 cases in a study, investors and strategists said. Moderna’s version, which uses similar experimental messenger RNA technology, is due to report results imminently.